131 related articles for article (PubMed ID: 23416308)
1. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist.
Lopatin U; Wolfgang G; Tumas D; Frey CR; Ohmstede C; Hesselgesser J; Kearney B; Moorehead L; Subramanian GM; McHutchison JG
Antivir Ther; 2013; 18(3):409-18. PubMed ID: 23416308
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
Lawitz E; Gruener D; Marbury T; Hill J; Webster L; Hassman D; Nguyen AH; Pflanz S; Mogalian E; Gaggar A; Massetto B; Subramanian GM; McHutchison JG; Jacobson IM; Freilich B; Rodriguez-Torres M
Antivir Ther; 2015; 20(7):699-708. PubMed ID: 25105516
[TBL] [Abstract][Full Text] [Related]
3. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
Gane EJ; Lim YS; Gordon SC; Visvanathan K; Sicard E; Fedorak RN; Roberts S; Massetto B; Ye Z; Pflanz S; Garrison KL; Gaggar A; Mani Subramanian G; McHutchison JG; Kottilil S; Freilich B; Coffin CS; Cheng W; Kim YJ
J Hepatol; 2015 Aug; 63(2):320-8. PubMed ID: 25733157
[TBL] [Abstract][Full Text] [Related]
4. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.
Janssen HLA; Brunetto MR; Kim YJ; Ferrari C; Massetto B; Nguyen AH; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Yoshida EM; Ahn SH; Tsai NCS; Fung S; Gane EJ
J Hepatol; 2018 Mar; 68(3):431-440. PubMed ID: 29104121
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses.
Fosdick A; Zheng J; Pflanz S; Frey CR; Hesselgesser J; Halcomb RL; Wolfgang G; Tumas DB
J Pharmacol Exp Ther; 2014 Jan; 348(1):96-105. PubMed ID: 24133297
[TBL] [Abstract][Full Text] [Related]
6. A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers.
Luk A; Jiang Q; Glavini K; Triyatni M; Zhao N; Racek T; Zhu Y; Grippo JF
Clin Transl Sci; 2020 Sep; 13(5):985-993. PubMed ID: 32268000
[TBL] [Abstract][Full Text] [Related]
7. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.
Lanford RE; Guerra B; Chavez D; Giavedoni L; Hodara VL; Brasky KM; Fosdick A; Frey CR; Zheng J; Wolfgang G; Halcomb RL; Tumas DB
Gastroenterology; 2013 Jun; 144(7):1508-17, 1517.e1-10. PubMed ID: 23415804
[TBL] [Abstract][Full Text] [Related]
8. TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.
Boni C; Vecchi A; Rossi M; Laccabue D; Giuberti T; Alfieri A; Lampertico P; Grossi G; Facchetti F; Brunetto MR; Coco B; Cavallone D; Mangia A; Santoro R; Piazzolla V; Lau A; Gaggar A; Subramanian GM; Ferrari C
Gastroenterology; 2018 May; 154(6):1764-1777.e7. PubMed ID: 29378197
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals.
Hu Y; Zhang H; Wu M; Liu J; Li X; Zhu X; Li C; Chen H; Liu C; Niu J; Ding Y
Expert Opin Investig Drugs; 2021 Mar; 30(3):263-269. PubMed ID: 33405993
[TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV.
Bergmann JF; de Bruijne J; Hotho DM; de Knegt RJ; Boonstra A; Weegink CJ; van Vliet AA; van de Wetering J; Fletcher SP; Bauman LA; Rahimy M; Appleman JR; Freddo JL; Janssen HL; Reesink HW
Aliment Pharmacol Ther; 2011 Aug; 34(4):443-53. PubMed ID: 21707679
[TBL] [Abstract][Full Text] [Related]
11. Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
Roethle PA; McFadden RM; Yang H; Hrvatin P; Hui H; Graupe M; Gallagher B; Chao J; Hesselgesser J; Duatschek P; Zheng J; Lu B; Tumas DB; Perry J; Halcomb RL
J Med Chem; 2013 Sep; 56(18):7324-33. PubMed ID: 23961878
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers.
Grippo JF; Folitar I; Passe S; Jiang Q; Rodriguez I; Fettner SH; Calleja E
Clin Transl Sci; 2021 Jul; 14(4):1524-1534. PubMed ID: 33742764
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects.
Reyes M; Lutz JD; Lau AH; Gaggar A; Grant EP; Joshi A; Mackman RL; Ling J; Tan SK; Ayithan N; Daffis S; Woo J; Wu P; Lam T; Fletcher SP; Kottilil S; Poonia B; Gane EJ; Mathias A; German P
Antivir Ther; 2020; 25(3):171-180. PubMed ID: 32667286
[TBL] [Abstract][Full Text] [Related]
14. Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7.
Boonstra A; Liu BS; Groothuismink ZM; Bergmann JF; de Bruijne J; Hotho DM; Hansen BE; van Vliet AA; van de Wetering de Rooij J; Fletcher SP; Bauman LA; Rahimy M; Appleman JR; Freddo JL; Reesink HW; de Knegt RJ; Janssen HL
Antivir Ther; 2012; 17(4):657-67. PubMed ID: 22301364
[TBL] [Abstract][Full Text] [Related]
15. Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1.
Riddler SA; Para M; Benson CA; Mills A; Ramgopal M; DeJesus E; Brinson C; Cyktor J; Jacobs J; Koontz D; Mellors JW; Laird GM; Wrin T; Patel H; Guo S; Wallin J; Boice J; Zhang L; Humeniuk R; Begley R; German P; Graham H; Geleziunas R; Brainard DM; SenGupta D
Clin Infect Dis; 2021 Jun; 72(11):e815-e824. PubMed ID: 33043969
[TBL] [Abstract][Full Text] [Related]
16. TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells.
Bam RA; Hansen D; Irrinki A; Mulato A; Jones GS; Hesselgesser J; Frey CR; Cihlar T; Yant SR
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799218
[TBL] [Abstract][Full Text] [Related]
17. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.
Dudek AZ; Yunis C; Harrison LI; Kumar S; Hawkinson R; Cooley S; Vasilakos JP; Gorski KS; Miller JS
Clin Cancer Res; 2007 Dec; 13(23):7119-25. PubMed ID: 18056192
[TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.
Schluep T; Lickliter J; Hamilton J; Lewis DL; Lai CL; Lau JY; Locarnini SA; Gish RG; Given BD
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):350-362. PubMed ID: 27739230
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.
Vicari AP; Schmalbach T; Lekstrom-Himes J; Morris ML; Al-Adhami MJ; Laframboise C; Leese P; Krieg AM; Efler SM; Davis HL
Antivir Ther; 2007; 12(5):741-51. PubMed ID: 17713157
[TBL] [Abstract][Full Text] [Related]
20. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).
Fidock MD; Souberbielle BE; Laxton C; Rawal J; Delpuech-Adams O; Corey TP; Colman P; Kumar V; Cheng JB; Wright K; Srinivasan S; Rana K; Craig C; Horscroft N; Perros M; Westby M; Webster R; van der Ryst E
Clin Pharmacol Ther; 2011 Jun; 89(6):821-9. PubMed ID: 21451504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
